Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02998047 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study of Lintuzumab-Ac225 in Patients With Refractory Multiple Myeloma
A Phase 1 study, sponsored by Actinium Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT02998047 is a Phase 1 study that was terminated before completion, run by Actinium Pharmaceuticals. The registered enrollment target is 2 participants.
The verdict
NCT02998047, a Phase 1 study, was terminated before completion, sponsored by Actinium Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
1. Establish the MTD of Lintuzumab-Ac225 as monotherapy 2. Establish overall response rate (ORR) where ORR = CR + sCR+ VGPR+PR) 3. Confirm the safety profile of the treatment regimen 4. Estimate progression-free survival (PFS) and overall survival
Interventions
- DRUG Lintuzumab AC 225
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2016-12 |
| Est. Completion | 2020-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02998047
The ClinicalTrials.gov registry entry for NCT02998047 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Actinium Pharmaceuticals, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lintuzumab AC 225 is the first listed.
NCT02998047 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02998047 about?
NCT02998047 is a clinical study titled "A Phase I Study of Lintuzumab-Ac225 in Patients With Refractory Multiple Myeloma". 1. Establish the MTD of Lintuzumab-Ac225 as monotherapy 2. Establish overall response rate (ORR) where ORR = CR + sCR+ VGPR+PR) 3. Confirm the safety profile of the treatment regimen 4. Estimate progression-free survival (PFS) and overall survival
What is the current status of trial NCT02998047?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2016-12. Estimated completion is 2020-05.
What interventions are being tested in trial NCT02998047?
The interventions under investigation include: Lintuzumab AC 225 (DRUG).
Who is sponsoring clinical trial NCT02998047?
This trial is sponsored by Actinium Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.